AR087701A1 - Derivados de pirazol con actividad inhibidora de sglt1 - Google Patents
Derivados de pirazol con actividad inhibidora de sglt1Info
- Publication number
- AR087701A1 AR087701A1 ARP120103173A ARP120103173A AR087701A1 AR 087701 A1 AR087701 A1 AR 087701A1 AR P120103173 A ARP120103173 A AR P120103173A AR P120103173 A ARP120103173 A AR P120103173A AR 087701 A1 AR087701 A1 AR 087701A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- saturated
- heterocycle
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporciona un compuesto pirazol que tiene una actividad inhibitoria de SGLT1 o una de sus sales farmacéuticamente aceptables, una composición farmacéutica que los comprende y su uso farmacéutico en el tratamiento de la diabetes mellitus tipo II. Reivindicación 1: Un compuesto o una de sus sales farmacéuticamente aceptables representado por la fórmula general (1) caracterizado porque Anillo Cy es (i) arilo C₆₋₁₀, (ii) cicloalquilo C₃₋₈ o (iii) cicloalquenilo C₃₋₈; n1 es 0, 1, 2, 3, ó 4; R¹ᵃ está representado (i) un átomo de halógeno, (ii) hidroxi, (iii) carboxi, (4) un grupo alquilo C₁₋₆, (v) un grupo alquenilo C₂₋₈, (vi) un grupo alquinilo C₂₋₈, (vii) un grupo alcoxi C₁₋₆, (viii) un grupo cicloalquilo C₃₋₆, (ix) un grupo haloalquilo C₁₋₆, (x) un grupo hidroxialquilo C₁₋₆, (xi) un grupo alcoxi C₁₋₆alquilo C₁₋₆, (xii) un grupo haloalcoxi C₁₋₆alquilo C₁₋₆, (xiii) un grupo alquil C₁₋₆sulfonilalquilo C₁₋₆, (xiv) un grupo haloalquil C₁₋₆sulfonilalquilo C₁₋₆, (xv) un grupo halodialquil C₁₋₆aminoalquilo C₁₋₆, (xvi) un grupo cicloalquil C₃₋₆alquinilo C₂₋₆, (xvii) un grupo haloalcoxi C₁₋₆, (xviii) un grupo carboxialcoxi C₁₋₆, (xix) un grupo alquil C₁₋₆sulfanilo, (xx) un grupo alquilsulfonilo C₁₋₆, (xxi) un grupo haloalquilsulfonilo C₁₋₆, (xxii) un grupo alquil C₁₋₈carbonilo, (xxiii) un grupo alquil C₁₋₆oxicarbonilo, (xxiv) un grupo representado por la fórmula (2) donde R⁵ es (a) un átomo de hidrógeno o (b) un grupo alquilo C₁₋₆, y R⁶ es (a) un grupo alquilo C₁₋₆ o (b) un grupo haloalquilo C₁₋₆, (xxv) un grupo alquilo C₆₋₁₀ de heterociclo saturado (el heterociclo saturado es un heterociclo saturado de 4 miembros a 6 miembros que tiene 1 a 2 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre), o (xxvi) un grupo oxialquilo C₁₋₆ de un heterociclo saturado (el heterociclo saturado es un heterociclo saturado de 4 miembros a 6 miembros que tiene 1 a 2 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre), con la condición de que cuando n1 es 2, 3, ó 4, R¹ᵃ puede ser igual o diferente; R²ᵃ es (i) un grupo hidroxialquilo C₁₋₈, (ii) un grupo cicloalquilo C₃₋₈alquilo C₁₋₆, (iii) un grupo aril C₆₋₁₀, alquilo C₁₋₆, (iv) un grupo alquilo C₆₋₁₀ de heterociclo saturado (el heterociclo saturado es un heterociclo saturado de 4 miembros a 6 miembros que tiene 1 a 2 heteroátomos seleccionados de nitrógeno, oxigeno, y azufre), (v) un grupo cicloalquilo C₃₋₈, (vi) un grupo haloalquilo C₁₋₆, (vii) un grupo alcoxi C₁₋₆alquilo C₁₋₆, (viii) un grupo halocicloalquilo C₃₋₈, (ix) un grupo arilo C₆₋₁₀ (el grupo arilo C₆₋₁₀ está opcionalmente sustituido con 1 a 4 sustituyentes seleccionados de (a) un átomo de halógeno, (b) hidroxi, (c) un grupo alquilo C₁₋₆, (d) un grupo alquenilo C₂₋₈, (e) un grupo alquinilo C₂₋₆, (f) un grupo alcoxi C₁₋₆, (g) un grupo haloalquilo C₁₋₆, (h) un grupo alcoxi C₁₋₆alquilo C₁₋₆, (i) un grupo haloalcoxi C₁₋₆, (j) un grupo hidoxialcoxi C₁₋₆, (k) un grupo alcoxi C₁₋₆alcoxi C₁₋₆, (l) un grupo carboxialcoxi C₁₋₆, (m) un grupo aril C₁₋₆alcoxi C₁₋₆, (n) un grupo alquil C₁₋₆sulfanilalcoxi C₁₋₆, (o) un grupo alquil C₁₋₆sulfonilalcoxi C₁₋₆, (p) un grupo aril C₆₋₁₀alcoxi C₁₋₆alcoxi C₁₋₆, (q) un grupo alcoxi C₁₋₆ del heterociclo saturado (el heterociclo saturado es un heterociclo saturado de 4 miembros a 6 miembros que tiene 1 a 2 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre, y está opcionalmente sustituido con 1 a 2 grupos alquilo C₁₋₆), (r) un grupo heterociclo oxi saturado (el heterociclo saturado es a heterociclo saturado de 4 miembros a 6 miembros que tiene 1 a 2 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre), (s) un grupo cicloalquil C₃₋₈oxi, (t) un grupo alcoxi C₁₋₆carboniloxi, y (u) un grupo alquil sulfonilo C₁₋₆), o (x) un grupo heterociclo saturado (el heterociclo saturado es un heterociclo saturado de 4 miembros a 6 miembros que tiene 1 a 2 heteroátomos seleccionados de nitrógeno, oxígeno, y azufre, y está opcionalmente sustituido con 1 a 4 grupos alquilo C₁₋₆); Anillo Cyᵃ es un grupo seleccionado de (i) un grupo representado por la fórmula (3) donde m2 es 1, 2 ó 3, m3 es 1, 2 ó 3, n3 es 1 ó 2, (ii) un grupo representado por la fórmula (4) donde m4 es 0, 1, 2 ó 3, m5 es 0, 1 ó 2, siempre que la suma de m4 y m5 sea 1 o más, (iii) un grupo representado por la fórmula (5) donde m4 es 0, 1, 2 ó 3, m5 es 0, 1 ó 2, siempre que la suma de m4 y m5 sea 1 o más, (iv) un grupo representado por la fórmula (6) donde m6 es 0, 1 ó 2, m7 es 0, 1 ó 2, siempre que la suma de m6 y m7 es 1 o más, (v) un grupo representado por la fórmula (7) donde m6 es 0, 1 ó 2, m7 es 0, 1 ó 2, siempre que la suma de m6 y m7 es 1 o más, (vi) un grupo representado por la fórmula (8) donde m8 es 1 ó 2, m9 es 1 ó 2, y (vii) un grupo representado por la fórmula (9) donde m8 es 1 ó 2, m9 es 1 ó 2, n2 es 0, 1, 2, 3, ó 4; R³ᵃ es (i) hidroxi, (ii) un grupo alquilo C₁₋₆ o (iii) un grupo hidroxialquilo C₁₋₆, con la condición de que cuando n2 sea 2, 3, o 4, R³ᵃ puede ser igual o diferente; R³ᵇ es (i) hidroxi, (ii) un grupo alquilo C₁₋₆ (que puede formar un grupo cicloalquilo C₃₋₆ junto con el carbono al que está unido y el carbono adyacente a este) o (iii) un grupo hidroxialquilo C₁₋₆, o (iv) cuando dos R³ᵇ se unen al mismo carbono, forman un grupo cicloalquilo C₃₋₆ junto con el carbono al que están unidos, siempre que cuando n2 sea 2, 3 ó 4, cada R³ᵇ puede ser igual o diferente; y R⁴ᵇ es (i) un átomo de hidrógeno, (ii) un grupo alquilo C₁₋₆, (iii) un grupo carboxialquilo C₁₋₆, (iv) un grupo haloalquilo C₁₋₆ o (v) un grupo alcoxi C₁₋₆alquilo C₁₋₆.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011188121 | 2011-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087701A1 true AR087701A1 (es) | 2014-04-09 |
Family
ID=47756400
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103173A AR087701A1 (es) | 2011-08-31 | 2012-08-28 | Derivados de pirazol con actividad inhibidora de sglt1 |
| ARP210102479A AR123441A2 (es) | 2011-08-31 | 2021-09-06 | Compuesto de pirazol |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102479A AR123441A2 (es) | 2011-08-31 | 2021-09-06 | Compuesto de pirazol |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US8846746B2 (es) |
| EP (3) | EP3524599A1 (es) |
| JP (5) | JP6091811B2 (es) |
| KR (1) | KR101989203B1 (es) |
| CN (1) | CN103917535B (es) |
| AR (2) | AR087701A1 (es) |
| AU (1) | AU2012302723B2 (es) |
| BR (1) | BR112014004651B1 (es) |
| CA (1) | CA2845127C (es) |
| CL (1) | CL2014000490A1 (es) |
| CO (1) | CO6890098A2 (es) |
| CY (1) | CY1121631T1 (es) |
| DK (1) | DK3199533T3 (es) |
| HK (1) | HK1202290A1 (es) |
| IL (1) | IL230763A (es) |
| MX (1) | MX359825B (es) |
| MY (1) | MY172422A (es) |
| PE (1) | PE20142343A1 (es) |
| PL (1) | PL3199533T3 (es) |
| RS (1) | RS58870B1 (es) |
| RU (1) | RU2617678C2 (es) |
| SG (1) | SG11201400244YA (es) |
| SI (1) | SI3199533T1 (es) |
| TW (1) | TWI549949B (es) |
| WO (1) | WO2013031922A1 (es) |
| ZA (1) | ZA201401071B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| EP2848254B1 (en) | 2012-05-07 | 2016-08-03 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative and use thereof for medical purposes |
| CA2891644A1 (en) | 2012-11-19 | 2014-05-22 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines |
| ES2694110T3 (es) | 2013-02-04 | 2018-12-18 | Taisho Pharmaceutical Co., Ltd. | Fármaco profiláctico o terapéutico para el estreñimiento |
| CN105358173B (zh) * | 2013-05-08 | 2022-09-02 | 休斯敦系统大学 | 靶向癌症治疗的egfr-sglt1相互作用 |
| CN105294703B (zh) * | 2015-10-23 | 2018-01-23 | 西安近代化学研究所 | 3,7,10‑三氧代‑2,4,6,8,9,11‑六氮杂[3,3,3]螺桨烷的合成方法 |
| WO2018029104A1 (de) | 2016-08-11 | 2018-02-15 | Bayer Cropscience Aktiengesellschaft | Substituierte pyrazolinylderivate, verfahren zu deren herstellung und ihre verwendung als herbizide und/oder pflanzenwachstumsregulatoren |
| DK3497084T3 (da) | 2016-08-15 | 2021-04-06 | Bayer Cropscience Ag | Fremgangsmåde til fremstilling af 3-amino-1-(2,6-disubstitueret phenyl)pyrazoler |
| TWI805699B (zh) * | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| JP7130588B2 (ja) * | 2018-04-04 | 2022-09-05 | 日本たばこ産業株式会社 | ヘテロアリールで置換されたピラゾール化合物及びその医薬用途 |
| BR112022003323A2 (pt) * | 2019-09-04 | 2022-05-24 | Japan Tobacco Inc | Método terapêutico ou profilático para diabetes usando medicina de combinação |
| JPWO2021045161A1 (es) * | 2019-09-04 | 2021-03-11 | ||
| US20230321044A1 (en) * | 2020-03-19 | 2023-10-12 | Japan Tobacco Inc. | Treatment or prevention method for chronic heart failure |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| PL353455A1 (en) * | 1999-08-12 | 2003-11-17 | Pharmacia Italia S.P.A. | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| US8084467B2 (en) * | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| WO2004014932A1 (ja) * | 2002-08-08 | 2004-02-19 | Kissei Pharmaceutical Co., Ltd. | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| JP2004137245A (ja) * | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| DE102004028241B4 (de) * | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
| AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| BRPI0518300A2 (pt) | 2004-11-23 | 2008-11-11 | Warner Lambert Co | derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia |
| WO2007034279A2 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | C3a antagonists and pharmaceutical compositions thereof |
| JP5069894B2 (ja) * | 2005-10-21 | 2012-11-07 | 田辺三菱製薬株式会社 | ピラゾール化合物 |
| EP1951678A1 (en) | 2005-10-21 | 2008-08-06 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity |
| TWI378922B (en) * | 2005-10-21 | 2012-12-11 | Mitsubishi Tanabe Pharma Corp | A pyrazole compound |
| US20070117858A1 (en) | 2005-11-23 | 2007-05-24 | Mingde Xia | Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators |
| CL2007002904A1 (es) * | 2006-10-10 | 2008-06-06 | Amgen Inc Soc Organizada Bajo | Compuestos derivados de pirazolopirimidina; composicion farmaceutica; y uso para tratar una enfermedad seleccionada de diabetes, obesidad, asma y artritis entre otras. |
| JP4994295B2 (ja) | 2007-04-20 | 2012-08-08 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| JP2010222298A (ja) * | 2009-03-24 | 2010-10-07 | Shionogi & Co Ltd | Ｎｐｙｙ５受容体拮抗作用を有するピロリドン誘導体 |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| US8163704B2 (en) * | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| NZ603156A (en) | 2010-03-30 | 2014-10-31 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
| CN102985405B (zh) | 2010-07-02 | 2016-07-06 | Aska制药株式会社 | 杂环化合物及p27Kip1分解抑制剂 |
| AU2011343039B2 (en) | 2010-12-14 | 2017-03-02 | Electrophoretics Limited | Casein kinase 1delta (CK1delta) inhibitors |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
-
2012
- 2012-08-28 AR ARP120103173A patent/AR087701A1/es active IP Right Grant
- 2012-08-30 EP EP19159289.8A patent/EP3524599A1/en active Pending
- 2012-08-30 SG SG11201400244YA patent/SG11201400244YA/en unknown
- 2012-08-30 CN CN201280050398.9A patent/CN103917535B/zh active Active
- 2012-08-30 SI SI201231595T patent/SI3199533T1/sl unknown
- 2012-08-30 DK DK17157922.0T patent/DK3199533T3/da active
- 2012-08-30 PE PE2014001489A patent/PE20142343A1/es active IP Right Grant
- 2012-08-30 WO PCT/JP2012/072066 patent/WO2013031922A1/ja active Application Filing
- 2012-08-30 EP EP17157922.0A patent/EP3199533B1/en active Active
- 2012-08-30 JP JP2012190429A patent/JP6091811B2/ja active Active
- 2012-08-30 MY MYPI2014000387A patent/MY172422A/en unknown
- 2012-08-30 BR BR112014004651-4A patent/BR112014004651B1/pt active IP Right Grant
- 2012-08-30 RU RU2014112048A patent/RU2617678C2/ru active
- 2012-08-30 RS RS20190581A patent/RS58870B1/sr unknown
- 2012-08-30 AU AU2012302723A patent/AU2012302723B2/en active Active
- 2012-08-30 TW TW101131507A patent/TWI549949B/zh active
- 2012-08-30 MX MX2014002552A patent/MX359825B/es active IP Right Grant
- 2012-08-30 US US13/599,665 patent/US8846746B2/en active Active
- 2012-08-30 EP EP12827193.9A patent/EP2784074A4/en not_active Withdrawn
- 2012-08-30 PL PL17157922T patent/PL3199533T3/pl unknown
- 2012-08-30 KR KR1020147004780A patent/KR101989203B1/ko active IP Right Grant
- 2012-08-30 CA CA2845127A patent/CA2845127C/en active Active
-
2014
- 2014-02-02 IL IL230763A patent/IL230763A/en active IP Right Grant
- 2014-02-11 ZA ZA2014/01071A patent/ZA201401071B/en unknown
- 2014-02-25 CO CO14038962A patent/CO6890098A2/es active IP Right Grant
- 2014-02-27 CL CL2014000490A patent/CL2014000490A1/es unknown
- 2014-07-29 US US14/445,500 patent/US20150183763A1/en not_active Abandoned
-
2015
- 2015-03-17 HK HK15102725.1A patent/HK1202290A1/xx unknown
-
2017
- 2017-02-08 JP JP2017021326A patent/JP2017082005A/ja not_active Ceased
- 2017-12-21 US US15/850,874 patent/US20180346449A1/en not_active Abandoned
-
2018
- 2018-05-02 JP JP2018088578A patent/JP2018115216A/ja not_active Ceased
-
2019
- 2019-05-08 CY CY20191100491T patent/CY1121631T1/el unknown
- 2019-11-07 US US16/677,523 patent/US20200317644A1/en not_active Abandoned
-
2020
- 2020-05-01 JP JP2020081097A patent/JP2020125348A/ja not_active Ceased
-
2021
- 2021-09-06 AR ARP210102479A patent/AR123441A2/es unknown
-
2022
- 2022-12-02 US US18/061,309 patent/US20230348438A1/en active Pending
-
2023
- 2023-05-02 JP JP2023075967A patent/JP2023087032A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087701A1 (es) | Derivados de pirazol con actividad inhibidora de sglt1 | |
| CY1125004T1 (el) | Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| UY37845A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
| CY1123533T1 (el) | Ν-αλκυλαρυλο-5-οξυαρυλο-οκταϋδρο-κυκλοπεντα [c] πυρρολια ως αρνητικοι αλλοστερικοι ρυθμιστες των nr2b | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| AR098912A1 (es) | Inhibidores de syk | |
| EA200702002A1 (ru) | Замещённые производные пиразолилоксифенила, применяемые в качестве гербицидов | |
| EA201992327A1 (ru) | Пептид, активирующий рецептор гип | |
| AR090862A1 (es) | Compuestos de tetrazolinona y su uso para combatir plagas | |
| NI200900032A (es) | Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3 | |
| ECSP20029790A (es) | Compuestos moduladores de sting y métodos de elaboración y uso | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR094300A1 (es) | Derivados de quinolonas | |
| AR111689A1 (es) | Tienopiridinas y benzotiofenos útiles como inhibidores de irak4 | |
| AR067691A1 (es) | Derivados heterociclicos de sulfonimidoil, composiciones plaguicidas que los contienen y usos de los mismos para el control de plagas. | |
| CO6351738A2 (es) | Compuestos organicos | |
| NI201000107A (es) | Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa. | |
| AR087668A1 (es) | Derivados de oxazina y su uso en el tratamiento de enfermedades | |
| ECSP088479A (es) | Derivados de oxadiazol | |
| AR103414A1 (es) | Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3 | |
| AR077367A1 (es) | 2- carboxamida -cicloamino-ureas sustituidas | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |